---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-062930"
form_type: "8-K"
ticker: "RNAZ"
cik: "0001829635"
company_name: "Transcode Therapeutics, Inc."
filed_at: "2023-05-22T23:59:59+00:00"
generated_at: "2026-06-14T18:28:29.021680+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# TransCode Therapeutics effects 1-for-20 reverse stock split to meet Nasdaq bid price rule

## Summary
- 1-for-20 reverse split effective 4:05 pm ET May 22, 2023; trading on split-adjusted basis begins May 23.
- Pre-split outstanding shares ~16,998,534 reduced to ~849,926 post-split shares.
- Reverse split intended to satisfy Nasdaq minimum $1.00 bid price continued listing requirement.
- No fractional shares issued; cash paid for fractional interests based on May 22 closing price.
- Trading symbol RNAZ unchanged; new CUSIP 89357L 204; Vstock Transfer LLC acting as exchange agent.

## SEC filing metadata
- accession: 0001104659-23-062930
- form_type: 8-K
- ticker: RNAZ
- cik: 0001829635
- company_name: Transcode Therapeutics, Inc.
- filed_at: 2023-05-22T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 3.03, 5.03, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1829635/000110465923062930/0001104659-23-062930-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1829635/000110465923062930/tm2316322d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-062930
- JSON: https://secwatch.observer/filing/0001104659-23-062930.json
- Plain text: https://secwatch.observer/filing/0001104659-23-062930.txt

## Key facts
- Governance Changes
  Transcode Therapeutics, Inc.: Filed Certificate of Amendment to effect a 1-for-20 reverse stock split of common stock (effective 2023-05-22).
  - Change: charter amendment
  - Effective: 2023-05-22
  source text: On May 19, 2023, TransCode Therapeutics, Inc. (the “Company”) filed a Certificate of Amendment (the “Certificate of Amendment”) to its Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to effect a 1-for-20 reverse stock split (the “Reverse Split”) of the Company’s issued and outstanding shares of common stock, par value $0.0001 per share (the “Common Stock”), as of 4:05 p.m. Eastern Time on May 22, 2023 (the “Effective Time”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1829635/000110465923062930/0001104659-23-062930-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.